Company intelligence / Profile preview

Vilaco

Ownership: Private
Development stage: Other

Overview

Vilacto Bio has developed the Lactoactive iTHER® platform for immunotherapy and vaccine applications. The company has successfully commercialized skincare products using earlier versions of its technology and is now focused on preclinical development for multiple disease areas including cancer, autoimmune disorders, and inflammatory conditions. No clinical results reported yet; programs are at the preclinical proof-of-concept stage.

Therapeutic areas: OncologyImmunologyHematologyDermatologyRheumatology
Modalities: NanoparticleImmunotherapyVaccineBiologic (colostrum-based)Small molecule (possible, based on drug development focus)
Industry: Biotech

Partnerships

Strategic alliances with contract research organizationscollaborations with scientific experts in relevant disease areas

Beyond the preview

Go deeper on Vilaco.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vilaco.

Explore the full profile